PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification o...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The EMBO journal Ročník 43; číslo 6; s. 1015 - 1042
Hlavní autoři:	Andronikou, Christina, Burdova, Kamila, Dibitetto, Diego, Lieftink, Cor, Malzer, Elke, Kuiken, Hendrik J, Gogola, Ewa, Ray Chaudhuri, Arnab, Beijersbergen, Roderick L, Hanzlikova, Hana, Jonkers, Jos, Rottenberg, Sven
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 15.03.2024
Témata:	Biomedical and Life Sciences DNA Damage DNA Repair DNA Repair Enzymes - genetics EMBO03 EMBO13 EMBO31 Exodeoxyribonucleases - genetics Flap Endonucleases - genetics Flap Endonucleases - metabolism Flap Endonucleases - therapeutic use Glycoside Hydrolases - genetics Glycoside Hydrolases - metabolism Humans Life Sciences Neoplasms - drug therapy Neoplasms - genetics Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism FEN1 PARG BRCA2 EXO1 DNA Repair
ISSN:	1460-2075, 0261-4189, 1460-2075
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!